Method Used to Measure MPR Influences Adherence Rate

November/December 2010, Vol 3, No 6 - Conference Highlights AMCP

The method used to measure medication adherence impacts the results of that measurement, and therefore researchers should use various methods depending on the overall goals of the study, according to researchers from the Accredo Health Group and Medco Health Solutions.

They compared 4 different ways of measuring med­ication possession ratio (MPR) in 8 specialty pharmacy therapeutic categories using 18 months of claims data. A patient’s first use of a drug was recorded (index date), and then all subsequent claims for 360 days were record­ed. The 8 drug categories were multiple sclerosis, rheumatoid arthritis, hepatitis C, pulmonary hyperten­sion, growth hormone, osteoporosis, oral oncology, and finally, the drug omalizumab (Xolair).

The 4 methods included (1) continuously eligible patients are followed for 360 days from the indexed pre­scription; (2) all patients with 2 or more prescriptions are included, but the last prescription is not included;

(3) the third approach is the same as the second one, but the last prescription is included; and (4) all patients with 1 prescription filled are included, which includes the last prescription.

In every case, the first method provides the lowest esti­mate of adherence rate, and each of the following meth­ods provides lower estimates than the next one above it. The difference in adherence rate between method 1 and method 4 for each of the drug categories was: 13% (mul­tiple sclerosis); 16.6% (rheumatoid arthritis); 44.4% (hepatitis C); 17.7% (pulmonary hypertension); 21.6% (growth hormone); 26.9% (osteoporosis); 16.4% (oral oncology); and finally, 21.6% (omalizumab).

Related Items
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
June 2018 Vol 11, No 4 published on June 25, 2018 in Conference Highlights AMCP
AMCP Nexus 2017 Highlights
December 2017 Vol 10, No 9 published on January 3, 2018 in Conference Highlights AMCP
Challenges and Opportunities in Managing Type 2 Diabetes
Laura Morgan
June 2017 Vol 10, No 4 published on June 22, 2017 in Conference Highlights AMCP
Payers’ Perspective: Incorporating Real-World Evidence in Patient Care
Lilly Ostrovsky
April 2017 Vol 10, No 2 published on April 18, 2017 in Conference Correspondent, Conference Highlights AMCP
Implications of Real-World Data and Pharmacoeconomics for Managed Care
Lilly Ostrovsky
May 2016 Vol 9, No 3 published on May 25, 2016 in Conference Highlights AMCP
Last modified: December 23, 2010
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME